During the past decade, Maine Center for Cancer Medicine-Scarborough conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 22 clinical trials were completed, i.e. on average, 104.8% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 10 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Maine Center for Cancer Medicine-Scarborough" #1 sponsor was "National Cancer Institute (NCI)" with 21 trials, followed by "Celgene" with 3 trials sponsored, "Alliance for Clinical Trials in Oncology" with 2 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored and "Dartmouth-Hitchcock Medical Center" with 2 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Maine Center for Cancer Medicine-Scarborough" #1 collaborator was "Cancer and Leukemia Group B" with 5 trials as a collaborator, "National Cancer Institute (NCI)" with 5 trials as a collaborator, "NCIC Clinical Trials Group" with 3 trials as a collaborator, "North Central Cancer Treatment Group" with 3 trials as a collaborator and "SWOG Cancer Research Network" with 3 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Maine Center for Cancer Medicine-Scarborough" are "Invasive Breast Carcinoma" (5 trials), "Recurrent Breast Carcinoma" (4 trials), "Stage IB Lung Non-Small Cell Carcinoma AJCC v7" (4 trials), "Stage IIIA Lung Non-Small Cell Cancer AJCC v7" (4 trials) and "Stage II Lung Non-Small Cell Cancer AJCC v7" (3 trials). Many other conditions were trialed in "Maine Center for Cancer Medicine-Scarborough" in a lesser frequency.

Most popular intervention types in "Maine Center for Cancer Medicine-Scarborough" are "Drug" (36 trials), "Other" (24 trials), "Biological" (20 trials), "Procedure" (6 trials) and "Radiation" (4 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (17 trials), "Quality-of-Life Assessment" (11 trials), "Bevacizumab" (9 trials), "Paclitaxel" (8 trials) and "Gemcitabine" (6 trials). Other intervention names were less common.

The vast majority of trials in "Maine Center for Cancer Medicine-Scarborough" are 39 trials for "All" genders, 6 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Maine Center for Cancer Medicine-Scarborough". undefined are not yet recruiting, 5 are recruiting, 22 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Maine Center for Cancer Medicine-Scarborough, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Maine Center for Cancer Medicine-Scarborough, 4 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 30 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".